Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early–intermediate stage hepatocellular carcinoma

索拉非尼 医学 肝细胞癌 危险系数 经导管动脉化疗栓塞 内科学 置信区间 加药 累积发病率 胃肠病学 入射(几何) 肿瘤科 阶段(地层学) 比例危险模型 外科 队列 光学 物理 古生物学 生物
作者
Teng‐Yu Lee,Lin Chen,Chiung Yu Chen,Tsang En Wang,Gin Ho Lo,Chi-Sen Chang,Yee Chao
出处
期刊:Medicine [Wolters Kluwer]
卷期号:96 (37): e7655-e7655 被引量:16
标识
DOI:10.1097/md.0000000000007655
摘要

Background/Objective: The survival benefit of treatment for unresectable hepatocellular carcinoma (HCC) with transcatheter arterial chemoembolization (TACE) combined with sorafenib remains uncertain. We compared the survival of patients treated with TACE and sorafenib with that of patients treated with TACE alone. Methods: This was a post hoc analysis of the Study in Asia of the Combination of TACE with Sorafenib in Patients with HCC (START) trial. All patients who received TACE and interrupted dosing of sorafenib for early or intermediate-stage HCC in Taiwan from 2009 to 2010 were recruited into the TACE and sorafenib group. They were randomly matched 1:1 by age, sex, Child–Pugh score, tumor size, tumor number, and tumor stage with patients from Taichung Veterans General Hospital in Taiwan who received TACE alone and who fulfilled the selection criteria of the START trial during the same time period (control group). Patient survival [cumulative incidence and hazard ratio (HR)] of the 2 groups were analyzed and compared. Results: The baseline characteristics of the 36 patients in each group were similar. Tumor response rates were significantly better in the TACE and sorafenib group (P < .04). Overall survival of the TACE and sorafenib group was also significantly better than that of the control (TACE alone) group over the 2 years [78%, 95% confidence interval (95% CI) 64–91 vs 49, 95% CI 32–66; P = .012]. In the multivariate regression analysis, TACE and sorafenib was found to be independently associated with a decreased risk of mortality (HR 0.33, 95% CI 0.12–0.89; P = .015). Multivariate stratified analyses verified this association in each patient subgroup (all HR < 1.0). Conclusion: With a high patient tolerance to an interrupted sorafenib dosing schedule, the combination of TACE with sorafenib was associated with improved overall survival in early–intermediate stage HCC when compared with treatment with TACE alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
2秒前
潇湘雪月发布了新的文献求助10
3秒前
3秒前
3秒前
4秒前
感动黄豆发布了新的文献求助10
4秒前
hhhblabla应助东方红采纳,获得10
6秒前
Poker应助sb采纳,获得10
7秒前
Ginger发布了新的文献求助10
7秒前
吃骨头的猫完成签到,获得积分10
7秒前
小李完成签到,获得积分10
7秒前
7秒前
8秒前
明芬发布了新的文献求助30
10秒前
10秒前
Smile完成签到,获得积分10
10秒前
Chaoe完成签到,获得积分10
13秒前
建国发布了新的文献求助10
14秒前
闪闪w发布了新的文献求助10
17秒前
淡烟流水完成签到,获得积分10
17秒前
俏皮芷蕊完成签到,获得积分10
18秒前
完美世界应助忐忑的阑香采纳,获得10
18秒前
华仔应助兴奋千兰采纳,获得10
23秒前
Ginger完成签到,获得积分10
24秒前
潇湘雪月发布了新的文献求助10
27秒前
科研通AI5应助科研通管家采纳,获得10
29秒前
29秒前
佳琳有乐完成签到,获得积分10
29秒前
29秒前
小蘑菇应助科研通管家采纳,获得10
29秒前
大模型应助科研通管家采纳,获得10
29秒前
CHAosLoopy应助科研通管家采纳,获得10
30秒前
桐桐应助科研通管家采纳,获得10
30秒前
今后应助cccyq采纳,获得10
30秒前
烟花应助科研通管家采纳,获得30
30秒前
情怀应助科研通管家采纳,获得10
30秒前
30秒前
隐形曼青应助科研通管家采纳,获得10
30秒前
在水一方应助科研通管家采纳,获得30
30秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989115
求助须知:如何正确求助?哪些是违规求助? 3531367
关于积分的说明 11253688
捐赠科研通 3269986
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882078
科研通“疑难数据库(出版商)”最低求助积分说明 809105